SeQuent Please Neo (BBraun Medical) is a balloon catheter for percutaneous transluminal coronary angioplasty. The balloon is coated with the antimitotic drug paclitaxel, with the aim of reducing restenosis. NICE issued medical technology guidance [MTG1] on this technology in 2010 and reviewed the guidance in 2016. NICE initiated an update of the guidance in 2017 and discontinued work in order for the technology to be included in a relevant clinical guideline update.
An update began in August 2017 using the processes and methods of the medical technologies programme. However, when the new evidence was presented to the medical technologies advisory committee, it considered that the guidance should be updated using another process. The committee was encouraged to hear from the clinical experts that the technology is now a standard treatment option in NHS practice. NICE has now decided that the guidance will be updated within a relevant clinical guideline. For more information, please refer to the update decision paper and to the committee papers in the history tab of the original guidance.
 
Status Discontinued
Decision Selected
Process MTG
ID number 302

Email enquiries

Stakeholders

External assessment group Newcastle & York Consortium
Manufacturers B.Braun Vascular Systems
Others Bridgewater Community Health Trust
  Department for Health and Social Care (DHSC)
  Healthcare Improvement Scotland (HIS)
  Johnson & Johnson Medical Ltd
  Medicines and Healthcare Products Regulatory Agency (MHRA)
  NHS England (NHSE)
Professional groups Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  BAPRAS
  British Association for Nursing in Cardiovascular Care
  British Cardiovascular Society
  Devices for Dignity
  Medical Technology Group
  The British In Vitro Diagnostics Association (BIVDA)

Timeline

Key events during the development of the guidance:

Date Update
10 July 2018 Discontinued: www.nice.org.uk/mtg1. An update began in August 2017 using the processes and methods of the medical technologies programme. However, when the new evidence was presented to the medical technologies advisory committee, it considered that the guidance should be updated using another process. The committee was encouraged to hear from the clinical experts that the technology is now a standard treatment option in NHS practice. NICE has now decided that the guidance will be updated within a relevant clinical guideline. For more information, please refer to the update decision paper and to the committee papers in the history tab of the original guidance.
08 December 2017 Committee meeting
30 August 2017 Scope published

For further information on our processes and methods, please see our CHTE processes and methods manual